Telavant: Roche: acquisition of Telavant from Roivant completed

(marketscreener.com) Roche has completed the acquisition of its subsidiary Telavant from Roivant for $7.1 billion, a transaction that was announced last October.This acquisition will enable the Swiss biopharmaceutical group to gain access to RVT-3101, a promising new treatment for inflammatory bowel diseases such as rectocolitis and Crohn's disease.The agreement...https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Roche-acquisition-of-Telavant-from-Roivant-completed-45571571/?utm_medium=RSS&utm_content=20231214